Cellebrite posts Q3 2026 results with ARR up 20% and raises adjusted EBITDA outlook
Cellebrite DI Ltd. reported third‑quarter 2026 financials on 12 November, showing annual recurring revenue of $528.5 million, a 20% year‑over‑year increase, and revenue of $149.0 million, up 18% YoY. GAAP diluted earnings per share were $0.10 and non‑GAAP diluted EPS were $0.17. The company lifted its 2026 adjusted EBITDA guidance to a range of $163 million‑$166 million and announced a plan to redomicile in the United States.
Why it matters
The higher ARR and raised EBITDA outlook suggest stronger operating profitability, which may improve cash‑flow generation and support the planned U.S. redomiciling, potentially expanding the investor base. The earnings beat and outlook lift drove the stock to rise about 5.9% in pre‑market trading.
Key facts
- 1Total annual recurring revenue (ARR) of $528.5 million, up 20% year‑over‑year. prnewswire.com
- 2Revenue of $149.0 million, up 18% year‑over‑year. prnewswire.com
- 3GAAP diluted earnings per share of $0.10. prnewswire.com
- 4Non‑GAAP diluted earnings per share of $0.17. prnewswire.com
- 5Adjusted EBITDA of $53.6 million, representing a 36.0% adjusted EBITDA margin. prnewswire.com
- 6Adjusted EBITDA outlook raised to $163 million‑$166 million for 2026. prnewswire.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.